Sienna Biopharmaceuticals Reports First Quarter 2018 Financial Results
14 mai 2018 09h05 HE
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today reported the Company’s financial results for the first quarter of 2018. “We are...
Sienna Biopharmaceuticals to Present at BAML Health Care Conference
11 mai 2018 09h05 HE
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., May 11, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief...
Sienna Biopharmaceuticals Appoints Caroline Van Hove as Chief Commercial Officer
22 mars 2018 08h05 HE
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., March 22, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the appointment of Caroline Van Hove as the Company’s first Chief...
Sienna Biopharmaceuticals Appoints John W. Smither as Chief Financial Officer
21 mars 2018 17h30 HE
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., March 21, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the appointment of John W. Smither as the Company’s Chief Financial...
Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
15 mars 2018 09h05 HE
|
Sienna Biopharmaceuticals, Inc.
-- Pipeline Includes Five Clinical-Stage Programs -- Data from Five Clinical Programs Expected, Beginning in 2H18 WESTLAKE VILLAGE, Calif., March 15, 2018 (GLOBE NEWSWIRE) -- Sienna...
Sienna Biopharmaceuticals Announces First Patient Dosed in Proof-of-Concept Trial of Topical by Design™ JAK Inhibitor SNA-125 for Atopic Dermatitis
12 mars 2018 06h05 HE
|
Sienna Biopharmaceuticals, Inc.
-- Trial to Enroll Approximately 30 Patients with Atopic Dermatitis -- Top-Line Results Expected in Fourth Quarter of 2018 WESTLAKE VILLAGE, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- Sienna...
Sienna Biopharmaceuticals to Present at Cowen and Company Health Care Conference
06 mars 2018 09h05 HE
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief...
Sienna Biopharmaceuticals Announces First Patient Dosed in First-in-Human Trial of Topical SNA-125
14 févr. 2018 09h05 HE
|
Sienna Biopharmaceuticals, Inc.
-- Trial to Enroll Approximately 15 Patients with Psoriasis-- Top-Line Results Expected in Third Quarter of 2018 WESTLAKE VILLAGE, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Sienna...
Sienna Biopharmaceuticals to Present at J.P. Morgan Healthcare Conference
04 janv. 2018 09h05 HE
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief...
Sienna Biopharmaceuticals Establishes Corporate Advisory Board
12 déc. 2017 09h05 HE
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the formation of a Corporate Advisory Board that will provide scientific,...